Background: Sensitivity to pegvisomant therapy is highly variable in patients with acromegaly but determinants of this variability are still unknown. Lack of exon 3 (d3-) of the growth hormone (GH) receptor (GHR) has been associated with increased biological activity of GH. Objective: To assess whether the presence of d3-GHR haplotype may have a role in predicting dose regimen and response to pegvisomant in acromegaly. Design: Case series. Setting: Institutional referral center at a tertiary care hospital. Patients: Ninenteen acromegalic patients with active disease after unsuccessful neurosurgery and somatostatin analog therapy. Measurements: before and 1, 3, 6 and 12 months after treatment with pegvisomant, IGF-I; GH receptor genotype, determined from peripheral blood by polymerase chain reaction. All patients started treatment with pegvisomant at 10 mg/daily and then increased the dose, according to a fixed schedule, during a 12-month follow-up until normalization of IGF-I levels. Results: d3-GHR patients required a significant lower dose of pegvisomant and shorter treatment time to normalize IGF-I. Conclusion: the GHR genotype could be useful in predicting dose and individual response to pegvisomant in acromegaly.
Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly / A. Bianchi, G. Mazziotti, L. Tilaro, V. Cimino, F. Veltri, E. Gaetani, G. Pecorini, A. Pontecorvi, A. Giustina, L. De Marinis. - In: PITUITARY. - ISSN 1386-341X. - 12:3(2009 Sep), pp. 196-199. [10.1007/s11102-008-0157-8]
Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly
V. Cimino;
2009
Abstract
Background: Sensitivity to pegvisomant therapy is highly variable in patients with acromegaly but determinants of this variability are still unknown. Lack of exon 3 (d3-) of the growth hormone (GH) receptor (GHR) has been associated with increased biological activity of GH. Objective: To assess whether the presence of d3-GHR haplotype may have a role in predicting dose regimen and response to pegvisomant in acromegaly. Design: Case series. Setting: Institutional referral center at a tertiary care hospital. Patients: Ninenteen acromegalic patients with active disease after unsuccessful neurosurgery and somatostatin analog therapy. Measurements: before and 1, 3, 6 and 12 months after treatment with pegvisomant, IGF-I; GH receptor genotype, determined from peripheral blood by polymerase chain reaction. All patients started treatment with pegvisomant at 10 mg/daily and then increased the dose, according to a fixed schedule, during a 12-month follow-up until normalization of IGF-I levels. Results: d3-GHR patients required a significant lower dose of pegvisomant and shorter treatment time to normalize IGF-I. Conclusion: the GHR genotype could be useful in predicting dose and individual response to pegvisomant in acromegaly.File | Dimensione | Formato | |
---|---|---|---|
s11102-008-0157-8.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
186.88 kB
Formato
Adobe PDF
|
186.88 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.